查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1750738

痛风药物市场规模、份额、趋势分析报告：依药物类别、疾病状况、通路、地区、细分预测，2025-2030 年

Gout Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents), By Disease Condition, By Distribution Channel (Hospital Pharmacy), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

痛风药物市场的成长与趋势：

根据 Grand View Research 的最新报告，预计到 2030 年全球痛风药物市场规模将达到 41.3 亿美元。

预计2025年至2030年，该市场的复合年增长率将达到6.45%。市场的成长可以归因于全球疾病负担的增加、政府和私人组织在民众中传播疾病意识的努力，以及该领域新治疗方法的最新进展。此外，临床研发线药物数量的增加也提供了丰厚的市场成长机会。

痛风的盛行率在全球范围内不断上升，这是推动市场成长的关键因素。例如，根据爱思唯尔的一篇论文，2021年澳洲痛风的盛行率为1.5%至2.9%。同样，加拿大和英国报告称，2021年痛风病例增幅分别约为4%和2.33%。老年人口的增长、不良饮食习惯（例如饮酒和摄取果糖）、久坐不动的生活方式以及肾臟疾病、心血管疾病和糖尿病等併发症的增多，进一步加剧了痛风的高盛行率。

强劲的临床试验管线和前景看好的新疗法上市预计将在预测期内推动市场成长。目前，江苏恆瑞医药股份有限公司的SHR4,640等候选药物正处于治疗痛风的3期临床试验阶段。同样，2023年3月，Selecta Biosciences, Inc.宣布其SEL-212的3期DISSOLVE I & II安慰剂对照随机临床试验取得了积极结果。 SEL-212适用于治疗慢性难治性痛风。

主要企业正在采取合作、併购、协议和金融投资等策略性倡议，以推动市场成长。例如，2021年6月，Horizo​​​​n Therapeutics plc与Arrowhead Pharmaceuticals合作开发了一种RNAi治疗剂，作为治疗未受控制的痛风的潜在药物。 2022年7月，该公司获得FDA扩大核准，将Krystexxa用于治疗未控制的痛风患者。该药物与免疫疗法和化疗药物胺基甲基叶酸合併使用。

此外，Horizo​​​​n 于 2023 年 3 月启动了全国肾臟月宣传活动「痛风除草」（Weed it G'out）。宣传活动以鲜花和野草为主题，展现尿酸与其对肾臟的影响之间的关联。该宣传活动旨在提高人们对痛风的认识，鼓励人们认真对待痛风并咨询专家。

痛风治疗药物市场报告重点

  • 由于处方率高、成本低、市场占有率高，非类固醇抗发炎药领域在 2024 年占据了最大的市场份额。
  • 根据疾病情况，急性病领域在 2024 年占总市场占有率的 65.77%，因为与慢性病相比，急性病患者数量更多。
  • 到 2024 年，零售药局将占据该领域最高的份额。然而，预计线上药局将成为预测期内成长最快的领域。
  • 由于痛风患者数量不断增加、个人对疾病治疗的认识程度较高以及医疗保健服务便利性等因素，北美将在 2024 年主导全球市场。

目录

第一章调查方法与范围

第二章执行摘要

3. 痛风药物市场变因、趋势与范围

  • 市场展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 痛风治疗市场分析工具
    • 产业分析—波特五力分析
    • PESTEL分析
    • 定价分析
    • 管道分析

第四章 痛风治疗市场：药物类别估计与趋势分析

  • 全球痛风药物市场：药物类别仪表板
  • 全球痛风药物市场：药物类别变化分析
  • 全球痛风药物市场（按药物类别和收益）
  • NSAIDs
  • 皮质类固醇
  • 秋水仙碱
  • 降尿酸药
  • 其他的

第五章痛风治疗市场：疾病状况评估及趋势分析

  • 全球痛风药物市场：疾病仪表板
  • 全球痛风治疗市场：病理状态变化分析
  • 全球痛风治疗市场（按疾病状况和收益）
  • 急性痛风
  • 慢性痛风
  • 慢性痛风市场估计与预测（2018-2030）

第六章痛风治疗市场：通路评估及趋势分析

  • 全球痛风药物市场：分销通路仪表板
  • 全球痛风药物市场：流通通路变化分析
  • 全球痛风药物市场（按分销管道和收益）
  • 医院药房
  • 零售药局
  • 网路药局

第 7 章痛风药物市场：按药物类别、疾病状态和通路进行区域估计和趋势分析。

  • 区域仪表板
  • 市场规模、预测趋势分析，2018 年至 2030 年：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • Key customers
    • Key company market share analysis, 2024
    • Takeda Pharmaceutical Company Limited
    • Novartis Pharmaceuticals Corporation
    • Regeneron Pharmaceuticals Inc.
    • Merck &Co., Inc.
    • AstraZeneca
    • Arrowhead Pharmaceuticals Inc.
    • AstraZeneca
    • Teijin Pharma Ltd.
    • GSK plc.
    • Zydus Group
Product Code: GVR-1-68038-717-9

Gout Therapeutics Market Growth & Trends:

The global gout therapeutics market size is anticipated to reach USD 4.13 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 6.45% from 2025 to 2030. The growth of the market is attributed to the global rise in disease burden, initiatives undertaken by government and private organizations to spread awareness among people, and the recent development of novel therapies in the space. Furthermore, the growing number of clinical pipeline drugs offers lucrative market growth opportunities.

The world is witnessing an increasing prevalence of gout, which is the key factor driving market growth. For instance, according to an Elsevier article, in 2021, Australia reported prevalence rates between 1.5% to 2.9% for gout. Similarly, in 2021, Canada and UK reported approximately 4% and 2.33% rise in disease cases respectively. High prevalence is further supported by the high geriatric population, improper diets such as consumption of alcohol and fructose, increasing sedentary lifestyle, and comorbidities like renal impairment, cardiovascular diseases, and diabetes.

The robust clinical trial pipeline and the anticipated launch of new therapeutics are expected to boost market growth over the forecast period. Presently, drug candidates like Jiangsu HengRui Medicine Co., Ltd.'s SHR4640 are in phase 3 clinical investigation for the treatment of gout. Similarly, in March 2023, Selecta Biosciences, Inc announced positive results for the Phase 3 DISSOLVE I & II placebo-controlled randomized clinical trials of SEL-212. SEL-212 is indicated for chronic refractory gout.

Key players are undertaking strategic initiatives such as collaborations, mergers and acquisitions, agreements, and financial investments, driving market growth. For instance, in June 2021, Horizon Therapeutics plc collaborated with Arrowhead Pharmaceuticals to develop RNAi therapeutic, a potential treatment for uncontrolled gout. In July 2022, the company received expanded FDA approval for Krystexxa for patients with uncontrolled gout. It is used in combination with immunotherapy and chemotherapy drug, methotrexate.

Additionally, in March 2023, Horizon organized a campaign, "Weed it G'out" for National Kidney Month. The campaign uses flowers and weeds to depict the correlation to the effect of uric acid on kidneys. The campaign aims to create awareness and urge people to take gout seriously and consult a specialist.

Gout Therapeutics Market Report Highlights:

  • NSAIDs segment accounted for the largest share of the market in 2024 due to the high prescription rate, low cost, and strong presence in the market.
  • Based on disease condition, the acute condition segment held 65.77% of the total market share in 2024, owing to a high patient pool compared to the chronic condition
  • In 2024, retail pharmacy held the highest segment share in the space. However, online pharmacy is expected to be the fastest-growing segment over the forecast period
  • North America dominated the global market in 2024 owing to factors such as increased gout cases, high awareness among individuals for disease treatment, and better healthcare access in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Disease Condition
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class outlook
    • 2.2.2. Disease Condition outlook
    • 2.2.3. Distribution Channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Gout Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Gout Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis
      • 3.3.4.1. Phase 1
      • 3.3.4.2. Phase 2
      • 3.3.4.3. Phase 2

Chapter 4. Gout Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Global Gout Therapeutics Market: Drug Class Dashboard
  • 4.2. Global Gout Therapeutics Market: Drug Class Movement Analysis
  • 4.3. Global Gout Therapeutics Market by Drug Class, Revenue
  • 4.4. NSAIDs
    • 4.4.1. NSAIDs market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Corticosteroids
    • 4.5.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Colchicine
    • 4.6.1. Colchicine market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Urate-Lowering Agents
    • 4.7.1. Urate-Lowering Agents market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Gout Therapeutics Market: Disease Condition Estimates & Trend Analysis

  • 5.1. Global Gout Therapeutics Market: Disease Condition Dashboard
  • 5.2. Global Gout Therapeutics Market: Disease Condition Movement Analysis
  • 5.3. Global Gout Therapeutics Market by Disease Condition, Revenue
  • 5.4. Acute Gout
    • 5.4.1. Acute Gout market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Chronic Gout
  • 5.6. Chronic Gout market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Gout Therapeutics Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global Gout Therapeutics Market: Distribution Channel Dashboard
  • 6.2. Global Gout Therapeutics Market: Distribution Channel Movement Analysis
  • 6.3. Global Gout Therapeutics Market by Distribution Channel, Revenue
  • 6.4. Hospital Pharmacy
    • 6.4.1. Hospital Pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Retail Pharmacy
    • 6.5.1. Retail Pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Online Pharmacy
    • 6.6.1. Online Pharmacy market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Gout Therapeutics Market: Regional Estimates & Trend Analysis by Drug Class, Disease Condition, and Distribution Channel.

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Takeda Pharmaceutical Company Limited
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Novartis Pharmaceuticals Corporation
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Regeneron Pharmaceuticals Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Merck & Co., Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. AstraZeneca
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Arrowhead Pharmaceuticals Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. AstraZeneca
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Teijin Pharma Ltd.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. GSK plc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Zydus Group
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 3 North America Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 4 North America Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 U.S. Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 6 U.S. Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 7 U.S. Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 Canada Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 9 Canada Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 10 Canada Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 Mexico Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 12 Mexico Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 13 Mexico Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Europe Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 15 Europe Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 16 Europe Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Germany Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 18 Germany Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 19 Germany Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 UK Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 21 UK Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 22 UK Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 France Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 24 France Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 25 France Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Italy Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 27 Italy Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 28 Italy Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Spain Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 30 Spain Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 31 Spain Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Denmark Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 33 Denmark Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 34 Denmark Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Sweden Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 36 Sweden Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 37 Sweden Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Norway Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 39 Norway Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 40 Norway Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 China Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 45 China Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 46 China Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Japan Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 48 Japan Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 49 Japan Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 India Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 51 India Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 52 India Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 South Korea Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 54 South Korea Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 55 South Korea Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Australia Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 57 Australia Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 58 Australia Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 Thailand Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 60 Thailand Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 61 Thailand Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 Latin America Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 63 Latin America Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 64 Latin America Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Brazil Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 66 Brazil Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 67 Brazil Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 Argentina Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 69 Argentina Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 70 Argentina Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 71 MEA Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 72 MEA Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 73 MEA Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 74 South Africa Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 75 South Africa Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 76 South Africa Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 77 Saudi Arabia Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 78 Saudi Arabia Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 79 Saudi Arabia Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80 UAE Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 81 UAE Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 82 UAE Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 Kuwait Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 84 Kuwait Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 85 Kuwait Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Gout Therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product and Distribution Channel segment snapshot
  • Fig. 10 Application segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Pharmaceutical market (USD Billion)
  • Fig. 13 Market dynamics
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Gout Therapeutics market: Drug Class outlook and key takeaways
  • Fig. 17 Gout Therapeutics market: Drug Class movement analysis
  • Fig. 18 Gout Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 NSAIDs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Corticosteroids market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Colchicine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Urate-Lowering Agents market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Gout Therapeutics market: Disease Condition outlook and key takeaways
  • Fig. 25 Gout Therapeutics market: Disease Condition movement analysis
  • Fig. 26 Acute Gout market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Chronic Gout market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Gout Therapeutics market: Distribution Channel and key takeaways
  • Fig. 29 Gout Therapeutics market: Distribution Channel movement analysis
  • Fig. 30 Hospital Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Retail Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Online Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Gout Therapeutics market revenue, by region, 2024 & 2030, (USD million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Key country dynamics
  • Fig. 37 Target disease prevalence
  • Fig. 38 U.S. gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 Target disease prevalence
  • Fig. 41 Canada gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Target disease prevalence
  • Fig. 44 Mexico gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Target disease prevalence
  • Fig. 47 Europe gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Target disease prevalence
  • Fig. 50 UK gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Target disease prevalence
  • Fig. 53 Germany gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Target disease prevalence
  • Fig. 56 France gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Target disease prevalence
  • Fig. 59 Spain gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Target disease prevalence
  • Fig. 62 Italy gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Target disease prevalence
  • Fig. 65 Denmark gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Target disease prevalence
  • Fig. 68 Sweden gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Target disease prevalence
  • Fig. 71 Norway gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Rest of Europe gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Asia Pacific gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Target disease prevalence
  • Fig. 76 Japan gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Target disease prevalence
  • Fig. 79 China gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Target disease prevalence
  • Fig. 82 India gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Target disease prevalence
  • Fig. 85 Australia gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Thailand gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 South Korea gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Rest of Asia Pacific gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Latin America gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Target disease prevalence
  • Fig. 94 Brazil gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Target disease prevalence
  • Fig. 97 Argentina gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Rest of Latin America gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 MEA gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Key country dynamics
  • Fig. 101 Target disease prevalence
  • Fig. 102 South Africa gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Key country dynamics
  • Fig. 104 Target disease prevalence
  • Fig. 105 Saudi Arabia gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Key country dynamics
  • Fig. 107 Target disease prevalence
  • Fig. 108 UAE gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 Target disease prevalence
  • Fig. 111 Kuwait gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 Rest of MEA gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)